Clinuvel Pharmaceuticals (ASX:CUV) said its CUV105 study showed staged repigmentation in non-segmental vitiligo patients following a combination treatment with its photoprotective drug Scensse (afamelanotide) and narrowband ultraviolet B (UVB) therapy, according to a Monday filing with the Australian bourse.
It highlighted four case reports that provide insight into how the treatment aids repigmentation in vitiligo patients, particularly those with darker skin types, the filing said.
After 26 weeks of treatment, Clinuvel sees that unaffected and repigmented skin returns to baseline complexion, the filing added.
The results align with Clinuvel's focus on addressing the needs of patients with significant medical requirements and its commitment to advancing afamelanotide as a treatment for non-segmental vitiligo, the filing added.
Clinuvel's CUV105 clinical trial is evaluating several key objectives in patients, with a key endpoint being a 50% improvement in the total vitiligo area scoring index.
Shares of the company fell nearly 2% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.